EUVIMEDEUVIMED entdecken
Crossref

Abstract 7331: Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Heart Failure with Ejection Fraction 50% or Less: A Propensity Matched Analysis

Abdussamad Syed, Mohammed Abdullah

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.7331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Abdussamad Syed und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

GLP-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 agonists are increasingly used in type 2 diabetes with heart failure and left ventricular ejection fraction (LVEF) 50% or less. Real-world data comparing tirzepatide with GLP-1 RAs in this population are scarce. Hypothesis: Tirzepatide is associated with fewer heart failure hospitalizations and lower healthcare utilization than GLP-1 RAs.

Methods

Using the TriNetX Research Network, we conducted a propensity score-matched retrospective cohort study among patients aged ≥40 with heart failure (LVEF ≤50%) and type 2 diabetes who initiated tirzepatide (Cohort 1, n=1,023 before matching) versus GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, lixisenatide, or exenatide) (Cohort 2, n=3,485 before matching). Patients with recent major cardiovascular events, advanced pulmonary disease, end-stage renal disease, or cirrhosis were excluded. After 1:1 propensity score matching for demographics and comorbidity burden, 923 patients per cohort were retained, with no significant differences between cohorts (Table 1). Outcomes, including all-cause mortality, heart failure hospitalizations, emergency department visits, acute myocardial infarction, acute kidney injury (AKI), and stroke were assessed over a 365-day follow-up window using risk estimates, Kaplan-Meier time-to-event analysis, and recurrent event analysis.

Results

Tirzepatide was associated with lower risk of heart failure hospitalization (21.2% vs 25.7%; risk difference –0.044; hazard ratio 0.771, 95% CI 0.638-0.932; p=0.024) and fewer ED visits (23.5% vs 27.8%; risk difference –0.043; p=0.033). Mortality was similar (4.3% vs 4.7%; p=0.736), as were acute MI, AKI, stroke, and short-stay encounters (Table 2). One-year LVEF did not differ (40.7% vs 39.8%; p=0.302). Kaplan-Meier analysis showed consistent separation favoring tirzepatide for both endpoints (log-rank p=0.007; Table 3).

Conclusions

In a propensity score-matched real-world cohort with type 2 diabetes and heart failure with ejection fraction 50% or less, tirzepatide was associated with significantly lower heart failure hospitalization and ED visits than GLP-1 RAs over one year, with no difference in mortality. This fills a real gap: incretin heart failure trials have centered on preserved ejection fraction and obesity, while the only GLP-1 RA trials in reduced ejection fraction were neutral with adverse signals. As among the first head-to-head comparisons in the reduced and mildly reduced range, these data, though observational, make a dedicated tirzepatide outcomes trial in this high-risk population a clear priority.

Zitieren

APA

Syed, A., & Abdullah, M. (2026). Abstract 7331: Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Heart Failure with Ejection Fraction 50% or Less: A Propensity Matched Analysis. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.7331

Vancouver

Syed A, Abdullah M. Abstract 7331: Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Heart Failure with Ejection Fraction 50% or Less: A Propensity Matched Analysis. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.7331

BibTeX
@article{Syed2026,
  author = {Syed, Abdussamad and Abdullah, Mohammed},
  title = {Abstract 7331: Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Heart Failure with Ejection Fraction 50% or Less: A Propensity Matched Analysis},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.7331}
}
Kostenlos starten →